WINTON GROUP Ltd Has $2.18 Million Holding in Chemed Co. (CHE)

WINTON GROUP Ltd Has $2.18 Million Holding in Chemed Co. (CHE)

WINTON GROUP Ltd raised its holdings in Chemed Co. (NYSE:CHE) by 9.2% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 6,828 shares of the company’s stock after purchasing an additional 577 shares during the quarter. WINTON GROUP Ltd’s holdings in Chemed were worth $2,182,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also bought and sold shares of CHE. Millennium Management LLC purchased a new stake in shares of Chemed in the second quarter valued at about $40,386,000. Point72 Asset Management L.P. purchased a new stake in shares of Chemed in the second quarter valued at about $24,586,000. Virginia Retirement Systems ET AL lifted its holdings in shares of Chemed by 750.5% in the second quarter. Virginia Retirement Systems ET AL now owns 77,400 shares of the company’s stock valued at $24,908,000 after purchasing an additional 68,300 shares in the last quarter. Renaissance Technologies LLC lifted its stake in shares of Chemed by 92.6% during the second quarter. Renaissance Technologies LLC now owns 137,900 shares of the company’s stock valued at $44,378,000 after buying an additional 66,300 shares during the period. Finally, First Trust Advisors LP lifted its stake in shares of Chemed by 370.3% during the third quarter. First Trust Advisors LP now owns 81,596 shares of the company’s stock valued at $26,076,000 after buying an additional 64,248 shares during the period. Institutional investors own 88.06% of the company’s stock.

CHE has been the topic of several recent analyst reports. Zacks Investment Research downgraded shares of Chemed from a “buy” rating to a “hold” rating in a research note on Tuesday, September 25th. Bank of America assumed coverage on shares of Chemed in a research note on Friday, October 12th. They set a “buy” rating and a $390.00 price target on the stock. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. The company presently has an average rating of “Buy” and an average price target of $332.00.

In other Chemed news, VP Naomi C. Dallob sold 5,500 shares of the stock in a transaction on Wednesday, November 7th. The shares were sold at an average price of $317.23, for a total transaction of $1,744,765.00. Following the transaction, the vice president now directly owns 11,122 shares in the company, valued at approximately $3,528,232.06. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Kevin J. Mcnamara sold 827 shares of the firm’s stock in a transaction dated Friday, November 9th. The stock was sold at an average price of $315.74, for a total transaction of $261,116.98. Following the completion of the transaction, the insider now owns 122,308 shares in the company, valued at $38,617,527.92. The disclosure for this sale can be found here. Insiders have sold a total of 24,953 shares of company stock worth $7,678,463 over the last quarter. 4.82% of the stock is currently owned by insiders.

CHE traded down $12.85 during trading hours on Wednesday, reaching $303.12. 62,378 shares of the stock traded hands, compared to its average volume of 106,743. The firm has a market cap of $5.07 billion, a price-to-earnings ratio of 56.55, a PEG ratio of 2.77 and a beta of 1.18. Chemed Co. has a fifty-two week low of $234.00 and a fifty-two week high of $335.99. The company has a current ratio of 1.14, a quick ratio of 1.11 and a debt-to-equity ratio of 0.23.

Chemed (NYSE:CHE) last released its quarterly earnings results on Monday, October 29th. The company reported $3.07 earnings per share for the quarter, beating the Zacks’ consensus estimate of $2.80 by $0.27. Chemed had a net margin of 11.73% and a return on equity of 35.13%. The business had revenue of $444.15 million during the quarter, compared to analyst estimates of $445.16 million. During the same period last year, the business earned $2.15 EPS. The business’s revenue was up 6.4% on a year-over-year basis. On average, analysts forecast that Chemed Co. will post 11.41 earnings per share for the current fiscal year.

The business also recently disclosed a quarterly dividend, which was paid on Monday, December 3rd. Shareholders of record on Monday, November 12th were paid a dividend of $0.30 per share. The ex-dividend date was Thursday, November 8th. This represents a $1.20 dividend on an annualized basis and a yield of 0.40%. Chemed’s dividend payout ratio (DPR) is 22.39%.

Chemed Profile

Chemed Corporation provides hospice and palliative care services in the United States. It operates through two segments, VITAS and Roto-Rooter. The VITAS segment offers direct medical services, as well as spiritual and emotional counseling services to terminally ill patients. This segment offers its services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers.

Recommended Story: What is Compound Annual Growth Rate (CAGR)?

Related posts

Leave a Comment